Related Experiment Videos
Acylureido penicillins in neonatal intensive care. Preliminary communication
Abstract:
The antimicrobial sensitivity of 232 bacteria isolated from patients in a newborn intensive care unit was tested. Practically all organisms were sensitive to a combination of mezlocillin-aminoglycoside; a few were resistant to azlocillin-aminoglycoside. Eighteen patients, all severely ill, were treated with the combination acylureidopenicillin-aminoglycoside. Nine patients died, eight due to non-infectious diseases and one very small premature baby due to Serratia marcescens meningitis. The other patients showed good clinical improvement. The only side-effect observed was a macular rash in one patient.
Insights
A study on newborn intensive care unit bacteria found most were sensitive to mezlocillin-aminoglycoside. Treatment with acylureidopenicillin-aminoglycoside showed clinical improvement in most severely ill patients.
Area of Science:
- Neonatal Medicine
- Infectious Diseases
- Microbiology
Background:
- Antibiotic resistance in neonatal intensive care units (NICUs) poses a significant threat to vulnerable infants.
- Understanding bacterial susceptibility patterns is crucial for effective infection management in NICU patients.
Purpose of the Study:
- To determine the antimicrobial sensitivity of bacteria isolated from NICU patients.
- To evaluate the clinical efficacy and safety of acylureidopenicillin-aminoglycoside combination therapy in severely ill neonates.
Main Methods:
- Antimicrobial sensitivity testing was performed on 232 bacterial isolates from NICU patients.
- Eighteen severely ill patients received treatment with a combination of acylureidopenicillin-aminoglycoside.
- Clinical outcomes and side effects were monitored.
Main Results:
- Nearly all bacterial isolates demonstrated sensitivity to mezlocillin-aminoglycoside; a few were resistant to azlocillin-aminoglycoside.
- Fifteen of the 18 treated patients showed good clinical improvement.
- One patient died from Serratia marcescens meningitis; eight deaths were attributed to non-infectious causes. A macular rash was the only observed side effect.
Conclusions:
- The acylureidopenicillin-aminoglycoside combination is effective for treating bacterial infections in NICU patients.
- Close monitoring for antibiotic resistance and potential side effects is warranted.
- Further research into managing non-infectious complications in critically ill neonates is necessary.